Phase
Condition
N/ATreatment
Transcatheter Tricuspid Valve Replacement
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Anatomically suitable for the MonarQ TTVR System
Symptomatic, tricuspid regurgitation (TR) that is severe or greater
Adequately treated for heart failure based upon medical standards
Hemodynamically stable
Exclusion
Exclusion Criteria:
Need for emergent or urgent surgery for any reason, any planned cardiac surgerywithin the next 12 months (365 days), or any planned percutaneous cardiac procedurewithin the next 90 days
Refractory Heart Failure (HF) that requires or required advanced intervention
Any condition, in the opinion of the investigator, making it unlikely the patientwill be able to complete all protocol procedures and follow-up.
Currently participating in another investigational biologic, drug or device study
Study Design
Study Description
Connect with a study center
Cedars-Sinai Medical Center
Los Angeles, California 90048
United StatesSite Not Available
Los Robles Hosptial and Medical Center
Thousand Oaks, California 91360
United StatesActive - Recruiting
North Shore University Hospital
Manhasset, New York 11030
United StatesActive - Recruiting
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania 19104
United StatesSite Not Available
Baylor Heart Hospital
Plano, Texas 75093
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.